BlossomHill Therapeutics, Inc. (BLSM)
| Market Cap | 501.02M |
| Revenue (ttm) | n/a |
| Net Income | -71.09M |
| EPS | -28.59 |
| Shares Out | 30.64M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 425,826 |
| Open | 16.32 |
| Previous Close | 16.24 |
| Day's Range | 16.22 - 16.89 |
| 52-Week Range | 15.25 - 17.25 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | n/a |
About BLSM
BlossomHill Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops small molecule medicines that address medical needs in cancer treatment. Its pipeline includes BH-30643, an OMNI-EGFR inhibitor in clinical development for advanced EGFR-mutant non-small cell lung cancer (NSCLC), BH-501284, and BH-30236, a macrocyclic CLK (Cdc2-like kinase) inhibitor being evaluated in patients with relapsed or refractory acute myeloid leukemia (R/R AML) and higher-risk myelodysplastic syndrome (HR-MDS). BlossomHill Therapeutics, Inc. was incor... [Read more]
Financial Performance
Financial StatementsNews
BlossomHill Therapeutics Stock (BLSM) Fails to Shine After $150M U.S. IPO
Shares in cancer-focused biotech firm BlossomHill Therapeutics ($BLSM) dropped nearly 3% in its stock market debut after it raised $150 million in its U.S. IPO. Below the IPO Price The…
BlossomHill Therapeutics opens at $15.75, IPO priced at $16.00
BlossomHill Therapeutics (BLSM) priced 9.375M shares at $16.00. The deal size was increased to 9.375M shares of common stock from 7.8M shares of common stock and priced within the $15.00-$17.00…
BlossomHill Therapeutics 9.375M share IPO priced at $16.00
The deal size was increased to 9.375M shares of common stock from 7.8M shares of common stock and priced within the $15.00-$17.00 range. JPMorgan, Leerink, Guggenheim, Lake Street and H.C.
BlossomHill Therapeutics Announces Pricing of Upsized $150 Million Initial Public Offering
SAN DIEGO, Aug. 06, 2026 (GLOBE NEWSWIRE) -- BlossomHill Therapeutics, Inc. , (“BlossomHill Therapeutics”), a clinical-stage biopharmaceutical company applying an intentional, chemistry-based approach...
BlossomHill Therapeutics 7.81M share IPO price range $15.00-$17.00
JPMorgan, Leerink, Guggenheim, Lake Street and H.C. Wainwright are acting as joint book running managers for the offering.
Latigo, BlossomHill launch US IPOs as biotech listings rebound
Drug developers Latigo Biotherapeutics and BlossomHill Therapeutics launched their U.S. initial public offerings on Monday riding the wave of biotech listings.
Cancer therapies biotech BlossomHill Therapeutics files for a $100 million IPO
BlossomHill Therapeutics, a Phase 2-ready biotech developing small molecule cancer therapies, filed on Friday with the SEC to raise up to $100 million in an initial public offering.
BlossomHill Therapeutics IPO Registration Document (S-1)
BlossomHill Therapeutics has filed to go public with an IPO on the NASDAQ